… the Pharmaceuticals and Medical Devices Agency (PMDA) on registrational trial … 2024, Travere received full FDA approval for sparsentan ( … compared with active control irbesartan. In Europe, FILSPARI® … new drug application (sNDA) for FILSPARI® for the treatment …

… an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) … two phase III clinical trials of sparsentan in Japan … profile compared with active control irbesartan. In Europe, it … new drug application (sNDA) for Filspari for the treatment of …

… an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) … profile compared with active control irbesartan. In Europe, it … new drug application (sNDA) for FILSPARI® for the treatment of … -on-phase-iii-clinical-trials-of-sparsentan-for-focal …

… treatment, as well as comparisons with global phase III trial … irbesartan. The FDA has accepted for review Travere’s supplemental New Drug … Application (sNDA) for Filspari for the treatment of … unmet need for approved treatment for IgA nephropathy in …

… Agency for Food and Drug Administration and Control ( … formulations) and cough treatments to vaccines (such as … injectables (like Norditropin), diabetes medicines (Januvia/Janumet), … B4-2317 Hydrochlorothiazide + Irbesartan Sanofi Aventis Nigeria Ltd …

… US Food and Drug Administration (FDA) has informed the … daily, oral medication the first non-immunosuppressive treatment for preventing … with maximum labeled dose irbesartan across adult and … , respectively, with the treatment effect of sparsentan strengthened …

… Jula Inrig, MD, chief medical officer of Travere Therapeutics, … endpoint for the combined treatment group, demonstrating a greater … consistent across all clinical trials conducted to date … dosed active control, irbesartan, including no drug-induced liver injury …

… phase 3 PROTECT clinical trial (NCT03762850)2, a randomized … review with the FDA, with a Prescription Drug User Fee … medicine indicated for FSGS. “[Sparsentan] is becoming a foundational treatment … safety of sparsentan versus irbesartan in patients with IgA …

… treatment with compound dendrobium iron combined with irbesartan … were provided by Hanhui Pharmaceutical Co., LTD.; Amlodipine … from Chengdu Remifensi Biotechnology Co., LTD. Chromatographic … herbal remedies and antihypertensive Western medications can …

… publication, number of trials, actual number of … medical treatment, which included oral irbesartan, while the treatment … formulations, thereby improving drug targeting and bioavailability … medicines for DKD treatment and management. Acta Pharmaceutica …